Back

Combined therapy with SGLT2i and GLP-1ra improves cardiovascular prognosis in a population with diabetes and overweigh or obesity. A real-world clinical practice study

26 August 2023 (13:15 - 13:50)
Organised by: Logo
Congress Presentation Part of: Diabetes and the heart (2) Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor David Garcia Vega

Ourense University Hospital Complex, Ourense (Spain)

5 More presentations in this session

Presentation thumbnail
Sex differences in the clinical profile of individuals with prediabetes and type 2 diabetes mellitus in the general population - results from the Gutenberg Health Study
Doctor V. Schmitt (Mainz, DE)
Abstract Slides Video
Presentation thumbnail
Time to act: the challenge of high incidence of diabetes and prediabetes in patients admitted with different cardiovascular diseases phenotypes
Doctor V. Medovchshikov (Aktobe, KZ)
Abstract Slides Video
Presentation thumbnail
Modifications of short-term heart rate variability in metabolic syndrome: a systematic review and meta-analysis
Mr J. Ortiz-Guzman (Valencia, ES)
Abstract Slides Video
Presentation thumbnail
Metabolic syndrome and long-term heart rate variability: a systematic review and meta-analysis
Mr J. Ortiz-Guzman (Valencia, ES)
Abstract Slides Video
Presentation thumbnail
Effect of sodium-glucose co-transporter inhibitors on arterial stiffness in patients with type 2 diabetes mellitus
Doctor J. Szigeti (Mohacs, HU)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes and the heart (2)

The Event

Event poster

ESC Congress 2023

26 August 2023 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Combined treatment with SGLT2i and GLP1ra compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
thumbnail
Congress Presentation
Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
thumbnail
Congress Presentation
Baseline characteristics and clinical outcomes of patients with type 2 diabetes and cardiovascular disease treated with GLP-1 receptor agonists and SGLT2 inhibitors

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources